Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK plus non-small cell lung cancer (NSCLC).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Stinchcombe, T; Doebele, RC; Wang, XF; Gerber, DE; Horn, L; Camidge, DR

Published Date

  • May 20, 2019

Published In

Volume / Issue

  • 37 / 15

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference Location

  • Chicago, IL

Conference Start Date

  • May 31, 2019

Conference End Date

  • June 4, 2019